Trials / Active Not Recruiting
Active Not RecruitingNCT05536804
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Tirzepatide Study of Renal Function in People With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease Using Multiparametric Magnetic Resonance Imaging
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D). The study will last about 56 weeks and include up to 12 visits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tirzepatide | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2023-02-08
- Primary completion
- 2026-09-01
- Completion
- 2026-10-01
- First posted
- 2022-09-13
- Last updated
- 2025-09-29
Locations
27 sites across 6 countries: United States, Austria, Canada, Denmark, Mexico, Netherlands
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05536804. Inclusion in this directory is not an endorsement.